According to NICE draft guidance, clinical trial evidence suggests romosozumab followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone. But there is uncertainty because the population in the clinical trial is different to the proposed population.

According to NICE, evidence on the safety and efficacy of the procedure is adequate to support its use provided that standard arrangements are in place for clinical governance, consent and audit. 

Risdiplam is recommended in NICE draft guidance as part of a managed access agreement.

Belimumab is the only medicine specifically licensed for treating systemic lupus erythematosus.